Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003587 · ClinicalTrials.gov registry record · Phase 2

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

A Phase 2 study, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
204
Enrollment target

NCT00003587 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 204 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003587, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
204 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of two different combination chemotherapy regimens in treating patients who have stage IIIB or stage IV non-small cell lung cancer

Interventions

  • DRUG cisplatin
  • DRUG carboplatin
  • DRUG docetaxel
  • DRUG paclitaxel
  • DRUG gemcitabine

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 1998-10
Est. Completion 2007-01
Phase Phase 2

Sponsor

SWOG Cancer Research Network

270 total trials

What the Registry Record Tells You About NCT00003587

The ClinicalTrials.gov registry entry for NCT00003587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.

NCT00003587 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00003587 about?

NCT00003587 is a clinical study titled "S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of two different combination chemotherapy regimens in treatin...

What is the current status of trial NCT00003587?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 1998-10. Estimated completion is 2007-01.

What interventions are being tested in trial NCT00003587?

The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), docetaxel (DRUG), paclitaxel (DRUG), gemcitabine (DRUG).

Who is sponsoring clinical trial NCT00003587?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.